Paper42228092
Intratumoral Regulatory T-cell Ablation Mediates Tumor Control Systemically without Autoimmunity.
Bockman A and 8 others. Cancer Res, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Intratumoral Regulatory T-cell Ablation Mediates Tumor Control Systemically without Autoimmunity. Papers, record 42228092. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42228092
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| T-Lymphocytes, Regulatory | Major topic |
| Autoimmunity | Major topic |
| Neoplasms | Major topic |
| Animals | |
| Mice | |
| Dendritic Cells | |
| Diphtheria Toxin | |
| Forkhead Transcription Factors | |
| Lymphocyte Depletion | |
| Humans |
Source PubMed
Grants7
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| DP2 CA247830 | NCI NIH HHS | United States | DP2CA247830 | PubMed | NIH RePORTER |
| R01 CA292818 | NCI NIH HHS | United States | R01CA292818 | PubMed | NIH RePORTER |
| 1DP2CA247830-01 | Foundation for the National Institutes of Health (FNIH) | DP2CA247830 | PubMed | NIH RePORTER | |
| Pew Charitable Trusts (Pew) | PubMed | PubMed | |||
| St. Baldrick's Foundation (SBF) | PubMed | PubMed | |||
| Gilead Sciences (Gilead) | PubMed | PubMed | |||
| R01CA292818 | Foundation for the National Institutes of Health (FNIH) | R01CA292818 | PubMed | NIH RePORTER |
References78
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 35296095 | Mechanisms of MHC-I Downregulation and Role in Immunotherapy Response. | Front Immunol | 2022 | https://conductscience.org/library/papers/35296095 | PubMed |
| 2 | 24777248 | Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. | Cancer Immunol Res | 2013 | https://conductscience.org/library/papers/24777248 | PubMed |
| 3 | 35354899 | The impact of CCR8+ regulatory T cells on cytotoxic T cell function in human lung cancer. | Sci Rep | 2022 | https://conductscience.org/library/papers/35354899 | PubMed |
| 4 | 37224815 | Tumor biology and immune infiltration define primary liver cancer subsets linked to overall survival after immunotherapy. | Cell Rep Med | 2023 | https://conductscience.org/library/papers/37224815 | PubMed |
| 5 | 18845758 | CTLA-4 control over Foxp3+ regulatory T cell function. | Science | 2008 | https://conductscience.org/library/papers/18845758 | PubMed |
| 6 | 19008445 | Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity. | Science | 2008 | https://conductscience.org/library/papers/19008445 | PubMed |
| 7 | 31455681 | A Phase I Study of the Anti-CC Chemokine Receptor 4 Antibody, Mogamulizumab, in Combination with Nivolumab in Patients with Advanced or Metastatic Solid Tumors. | Clin Cancer Res | 2019 | https://conductscience.org/library/papers/31455681 | PubMed |
| 8 | 40181089 | Adoptively transferred tumor-specific IL-9-producing cytotoxic CD8+ T cells activate host CD4+ T cells to control tumors with antigen loss. | Nat Cancer | 2025 | https://conductscience.org/library/papers/40181089 | PubMed |
| 9 | 36352891 | Differential expression of CCR8 in tumors versus normal tissue allows specific depletion of tumor-infiltrating T regulatory cells by GS-1811, a novel Fc-optimized anti-CCR8 antibody. | Oncoimmunology | 2022 | https://conductscience.org/library/papers/36352891 | PubMed |
| 10 | 28486109 | Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy. | Cancer Cell | 2017 | https://conductscience.org/library/papers/28486109 | PubMed |
| 11 | 20332236 | Multiple antitumor mechanisms downstream of prophylactic regulatory T-cell depletion. | Cancer Res | 2010 | https://conductscience.org/library/papers/20332236 | PubMed |
| 12 | 36736322 | Tissue-specific abundance of interferon-gamma drives regulatory T cells to restrain DC1-mediated priming of cytotoxic T cells against lung cancer. | Immunity | 2023 | https://conductscience.org/library/papers/36736322 | PubMed |
| 13 | 29107330 | Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution. | Cell | 2017 | https://conductscience.org/library/papers/29107330 | PubMed |
| 14 | 37392735 | CXCR3 expression in regulatory T cells drives interactions with type I dendritic cells in tumors to restrict CD8+ T cell antitumor immunity. | Immunity | 2023 | https://conductscience.org/library/papers/37392735 | PubMed |
| 15 | 11137993 | The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. | Nat Genet | 2001 | https://conductscience.org/library/papers/11137993 | PubMed |
| 16 | 35622903 | Intratumoral immunotherapy relies on B and T cell collaboration. | Sci Immunol | 2022 | https://conductscience.org/library/papers/35622903 | PubMed |
| 17 | 36351377 | Dendritic cells can prime anti-tumor CD8+ T cell responses through major histocompatibility complex cross-dressing. | Immunity | 2022 | https://conductscience.org/library/papers/36351377 | PubMed |
| 18 | 10553041 | Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. | J Immunol | 1999 | https://conductscience.org/library/papers/10553041 | PubMed |
| 19 | 17676052 | A spatially and temporally restricted mouse model of soft tissue sarcoma. | Nat Med | 2007 | https://conductscience.org/library/papers/17676052 | PubMed |
| 20 | 37256255 | Targeted TLR9 Agonist Elicits Effective Antitumor Immunity against Spontaneously Arising Breast Tumors. | J Immunol | 2023 | https://conductscience.org/library/papers/37256255 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CCR8 | 1237 | PubTator's text mining | https://conductscience.org/library/genes/1237 | NCBI Gene |
| CD4 | 920 | PubTator's text mining | https://conductscience.org/library/genes/920 | NCBI Gene |
| CD8A | 925 | PubTator's text mining | https://conductscience.org/library/genes/925 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42228092
GET https://conductscience.org/api/papers/v1/42228092/references?page=2